Han Zhang1, Yongchang Zheng2, Duolima Han1, Jizhou Lu3, Shutao Yin1, Hongbo Hu1, Chong Zhao1. 1. Beijing Advanced Innovation Center for Food Nutrition and Human Health, College of Food Science and Nutritional Engineering, China Agricultural University, Haidian District, Beijing100080, China. 2. Department of Liver Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing100730, China. 3. Department of Liver Surgery, The Third People's Hospital of Gansu Province, Chengguan District, Lanzhou, Gansu 730030, China.
Abstract
The most common saturated fatty acid in the human diet is palmitic acid (PA), and emerging evidence suggests that it may have anticancer activity. Methylseleninic acid (MSeA), the most commonly used selenium derivative in humans, has specific cytotoxic effects on several cancer cells. However, it is generally considered that HepG2 cells are insensitive to MSeA-induced death. In our current research, we found that the addition of PA increased the sensitivity of HepG2 cells to low-dose MSeA-induced apoptosis. The anticancer efficacy of the MSeA/PA combination was also demonstrated in a HepG2 xenograft model. Further experiments revealed that IRE1 inhibition significantly enhanced the PA-induced apoptosis, indicating the prosurvival function of IRE1 in PA treatment of HepG2 cells. The combination of PA and MSeA attenuated the IRE1 pathway and increased the expressions of phospha-eIF2α and GADD153/C/EBP homologous protein (CHOP), contributing to the PA/MSeA combination-induced mitochondria-dependent apoptosis in HepG2 cells. In addition, PA downregulated the expression of the glucose transporter GLUT1 and restricted glucose metabolism, thus promoting the apoptosis of tumor cells. Considering the lipotoxicity of PA, L02 human normal hepatocytes were used to evaluate the effect of MSeA on the lipotoxicity caused by PA. Interestingly, MSeA prevented PA-induced lipotoxicity in L02 cells. Our findings provided evidence that PA may be a promising and excellent sensitizer for improving the anticancer effect of MSeA in hepatoma chemotherapy.
The most common saturated fatty acid in the human diet is palmitic acid (PA), and emerging evidence suggests that it may have anticancer activity. Methylseleninic acid (MSeA), the most commonly used selenium derivative in humans, has specific cytotoxic effects on several cancer cells. However, it is generally considered that HepG2 cells are insensitive to MSeA-induced death. In our current research, we found that the addition of PA increased the sensitivity of HepG2 cells to low-dose MSeA-induced apoptosis. The anticancer efficacy of the MSeA/PA combination was also demonstrated in a HepG2 xenograft model. Further experiments revealed that IRE1 inhibition significantly enhanced the PA-induced apoptosis, indicating the prosurvival function of IRE1 in PA treatment of HepG2 cells. The combination of PA and MSeA attenuated the IRE1 pathway and increased the expressions of phospha-eIF2α and GADD153/C/EBP homologous protein (CHOP), contributing to the PA/MSeA combination-induced mitochondria-dependent apoptosis in HepG2 cells. In addition, PA downregulated the expression of the glucose transporter GLUT1 and restricted glucose metabolism, thus promoting the apoptosis of tumor cells. Considering the lipotoxicity of PA, L02 human normal hepatocytes were used to evaluate the effect of MSeA on the lipotoxicity caused by PA. Interestingly, MSeA prevented PA-induced lipotoxicity in L02 cells. Our findings provided evidence that PA may be a promising and excellent sensitizer for improving the anticancer effect of MSeA in hepatoma chemotherapy.
Hepatocellular carcinoma (HCC) has high
morbidity and mortality
rates, and there is currently no clear treatment method. Lipids are
basic components and energy sources of cells, and changes in lipid
composition are increasingly believed to be closely related to the
occurrence of cancer. Palmitic acid (PA), a long-chain saturated fatty
acid, is the most common saturated fatty acid in dietary fats. For
example, in peanut oil, PA accounts for about 13% of the total fatty
acid, 65% in butter, 42% in lard, 15% in soybeans, and so on.[1] In addition, PA is the most common saturated
fatty acid in our body, accounting for about 65% of the human saturated
fatty acids.[2] Although some studies have
shown that PA has potential tumorigenic properties, there are also
reports that PA decreases the cell membrane fluidity of hepatocellular
carcinoma cells and restricts glucose metabolism.[1,3] Moreover,
PA downregulates the expression levels of mTOR and STAT3, reduces
cancer cell proliferation, impairs cell invasiveness, and inhibits
tumor growth in LM3 xenograft mouse models.[3] In breast cancer, PA induces a functionally different transcription
program, which reduces the expressions of HER2 and HER3.[1,4] Additionally, PA plays an important role in the secretion of exosomes
from cancer cells.[5]Selenium is an
essential trace element for the human body, and
it plays an indispensable role in organisms, such as anticancer, immune
regulation, detoxification, and antioxidation. Lack of selenium can
cause a series of diseases.[6] Methylseleninic
acid (MSeA) is an important organoselenium derivative, which generates
methylselenol through its spontaneous reaction with free thiols to
exert anticancer effects.[7] Because the
activity of MSeA does not depend on the expression of lyases, such
as methionine γ-lyase, it may be a more effective and promising
antitumor drug than other organoselenium compounds. Some experimental
and clinical research data indicate that low selenium intake is a
related risk factor for primary liver cancer (PLC), and the liver
is particularly sensitive to the supply of selenium.[8,9] However, high selenium intake can lead to diabetes and cardiovascular
diseases.[10−12] Although studies have confirmed that MSeA can induce
apoptosis in HepG2humanliver cancer cells, its dosage seems to have
potential health risks.[13]The endoplasmic
reticulum (ER) is an important subcellular organelle,
which plays a vital role in the process of protein synthesis, folding
and maturation.[14,15] For ER-mediated protein folding,
the unfolded protein response (UPR) can maintain a homeostatic balance
between the demand and capacity of mammalian cells.[15−19] If the UPR fails to manage misfolded and unfolded
proteins, the cellular apoptosis pathways are triggered.[1,19,20] ER stress often induces cell
apoptosis via CCAAT/enhancer-binding protein homologous protein (CHOP),
which induces caspase activation through genes such as Bim[21] and DR5.[22−25] Lipotoxicity can induce cell apoptosis through a
variety of mechanisms, including ER stress.[26] Previous studies have shown that in PA-induced ER stress, the activation
of JNK and the upregulation of CHOP are downstream events.[27] MSeA has also been shown to cause overall redox
reactions to modify proteins. These changes are intracellular stress
caused by unfolded or misfolded proteins. Recent research has provided
strong evidence to support the important role of ER stress in the
anticancer effect of selenium.[28] In PC3
cells, MSeA induces the hallmark signals of ER stress, including upregulation
of phosphorylated PERK, phosphorylated eIF2α, and glucose-related
proteins Bip and GRP94. Moreover, CHOP/GADD153 may be a key transcription
factor in the process of MSeA-induced apoptosis.[28]In our study, PA enhanced the sensitivity of HepG2
cells to low-dose
MSeA in vitro and in vivo. In this
process, IRE1 played a prosurvival role in PA-induced cell death.
MSeA inhibited PA-induced p-IRE1α and further enhanced p-eIF2α
and CHOP levels, which contributed to the PA/MSeA combination-induced
mitochondria-dependent apoptosis in HepG2 cells.
Results
Combination
of MSeA and PA Increases the Anticancer Effect of
MSeA In Vitro and In Vivo
First, we used crystal violet staining to detect the changes in cell
viability induced by MSeA in the presence or absence of PA in HepG2
cells. Exposure to 2 μM MSeA alone did not cause a significant
change in the cell survival rate, while the combination of MSeA and
PA dramatically increased cytotoxicity (Figure A). Next, we used Annexin V/PI staining to
further prove this effect. As shown in Figure B, the MSeA/PA combination significantly
enhanced cell death compared with the effect of MSeA and PA alone.
Taking into account the lipotoxicity of PA, we used L02 human normal
hepatocytes to evaluate the changes in cell viability. As shown in Figure C, exposure to PA
caused a significant decrease in cell viability, while MSeA greatly
ameliorated the inhibition effect of PA on cell viability. Then, we
used Annexin V/PI staining to further detect the influence on L02
cells. As shown in Figure D, PA induced an increase in apoptosis, which was significantly
reduced after MSeA treatment.
Figure 1
Combined use of MSeA and PA enhanced the cytotoxicity
in HepG2
liver cancer cells, and MSeA inhibited PA-induced apoptosis in L02
human normal liver cells. The cells were treated with the specified
concentration of MSeA and/or PA for 24 h, and then the cells were
collected for viability analysis. In the cell migration experiment,
a sterile microtube tip was used to draw a line on the monolayer of
cells to form a linear scratch, and then the effect of the drug on
cell migration was observed. (A) Combination effect of PA/MSeA on
HepG2 cells measured by crystal violet staining. (B) Promotive effect
of PA on MSeA-induced apoptosis assessed by Annexin V/PI in HepG2
cells. (C) Inhibitory effect of MSeA on the total number of L02 cells
caused by PA examined by crystal violet staining. (D) Protective effect
of MSeA on PA-induced apoptosis in L02 examined by Annexin V/PI staining.
(E) Representative microscopy images showed the reduction of HepG2
cell migration under MSeA and/or PA treatment. (F) Analysis of the
experimental wound closure.
Combined use of MSeA and PA enhanced the cytotoxicity
in HepG2liver cancer cells, and MSeA inhibited PA-induced apoptosis in L02
human normal liver cells. The cells were treated with the specified
concentration of MSeA and/or PA for 24 h, and then the cells were
collected for viability analysis. In the cell migration experiment,
a sterile microtube tip was used to draw a line on the monolayer of
cells to form a linear scratch, and then the effect of the drug on
cell migration was observed. (A) Combination effect of PA/MSeA on
HepG2 cells measured by crystal violet staining. (B) Promotive effect
of PA on MSeA-induced apoptosis assessed by Annexin V/PI in HepG2
cells. (C) Inhibitory effect of MSeA on the total number of L02 cells
caused by PA examined by crystal violet staining. (D) Protective effect
of MSeA on PA-induced apoptosis in L02 examined by Annexin V/PI staining.
(E) Representative microscopy images showed the reduction of HepG2
cell migration under MSeA and/or PA treatment. (F) Analysis of the
experimental wound closure.Furthermore, we performed the wound-healing experiment to assess
the effect of MSeA/PA treatment on the migration characteristics in
HepG2 cells. As shown in Figure E,F, the MSeA/PA combination effectively inhibited
the migration of HepG2 cells.To further verify the synergy
of MSeA/PA in vivo, we established the HepG2 xenograft
mouse model. When the average
tumor volume reached about 100–120 mm3, the HepG2tumor-bearing mice were given MSeA and/or PA, respectively. The dose
of MSeA was 2 mg/kg/day, and the dose of PA was 10.26 mg/kg/day. As
shown in Figure A,
the drug treatments did not cause a significant decrease in the weight
of the mice. Moreover, the dose of each agent alone slightly reduced
the size and weight of the tumor, while the MSeA/PA combination further
inhibited the tumor growth (Figure B–D). These above-mentioned data indicate that
the combination of MSeA and PA exerted better anticancer effects both in vitro and in vivo. Additionally, MSeA
can protect against PA-induced cytotoxicity in L02 human normal liver
cells and will not have greater toxic effects on normal liver cells.
Figure 2
Cotreatment
of MSeA and PA increases the tumor inhibitory effect
on the HepG2 xenograft model. BALB/c athymic nude mice bearing HepG2
xenograft tumors were treated with MSeA and/or PA by gavage for 20
consecutive days; the dose of MSeA was 2 mg/kg/day, and the dose of
PA was 10.26 mg/kg/day. (A) Body weight kinetics of nude mice bearing
HepG2 xenograft tumors. Photograph (B) and the final tumor weight
(C) in the HepG2 xenograft model. (D) Reduction in the final weight
of tumors through MSeA or/and PA treatment.
Cotreatment
of MSeA and PA increases the tumor inhibitory effect
on the HepG2 xenograft model. BALB/c athymic nude mice bearing HepG2
xenograft tumors were treated with MSeA and/or PA by gavage for 20
consecutive days; the dose of MSeA was 2 mg/kg/day, and the dose of
PA was 10.26 mg/kg/day. (A) Body weight kinetics of nude mice bearing
HepG2 xenograft tumors. Photograph (B) and the final tumor weight
(C) in the HepG2 xenograft model. (D) Reduction in the final weight
of tumors through MSeA or/and PA treatment.
IRE1 Plays an Anti-Apoptotic Role in MSeA/PA Combination-Induced
Cell Death
Previous studies have demonstrated that the kinases,
PERK and IRE1, alleviate ER stress by orchestrating the UPR.[29] Under irresolvable ER stress, PERK activity
persists, whereas IRE1 paradoxically attenuates, eventually promoting
cell death. In this experiment, we measured the expression changes
in the key ER stress markers, IRE1α and eIF2α. Western
blot analysis demonstrated that the MSeA/PA combination treatment
increased the phosphorylation of eIF2α but decreased the phosphorylation
of IRE1α (Figure A), indicating that some coordination between two branches of the
UPR determines the apoptotic cell fate. The transcription factor,
CHOP, is a key mediator of ER stress-induced apoptosis, and excessive
or abnormal ER stress can lead to the activation of CHOP and ultimately
cause cell death. We found that MSeA/PA also caused a significant
upregulation of CHOP. Additionally, the expression of Bip increased.
To determine the essential role of IRE1 in MSeA/PA-induced apoptosis
in HepG2 cells, we used 4μ8C, an IRE1 inhibitor, to evaluate
apoptosis induced by PA. We found that the inhibition of IRE1 by 4μ8C
greatly increased PA-induced apoptosis (Figure C), as well as the expression of CHOP (Figure D). Furthermore,
MSeA/PA inhibited the anti-apoptotic effect of IRE1 in the xenograft
mouse model (Figure E). It was noteworthy that p-IRE1α was also inhibited by MSeA/PA
in L02 (Figure B),
suggesting that the IRE1 signaling pathway might play a distinct role
in different cell types and different periods of intracellular stress.
These results support the key role of ER stress, especially IRE1 inactivation
in MSeA/PA-induced CHOP upregulation and cell death.
Figure 3
IRE1 attenuation downstream
of PERK inhibits cytoprotective adaptation and promotes apoptosis.
(A) Synergistic effect of PA on MSeA-mediated ER stress in cell culture.
In the presence or absence of PA, HepG2 cells were exposed to MSeA
for 24 h, and then western blotting was used to evaluate the changes
of key ER stress markers. (B) Effect of PA and/or MSeA on the ER stress
makers in L02 cells were analyzed by western blotting. (C) Total apoptosis
induced by inhibition of IRE1 and exposure to PA in HepG2. (D) Effect
of inhibiting IRE1α and exposure to PA on the expression level
of cleaved-poly (ADP-ribose) polymerase (PARP) and ER stress-related
proteins in HepG2. (E) Effects of MSeA, PA, and the combination on
cleaved-PARP and phosphorylation of IRE1 measured by western blot in vivo.
IRE1 attenuation downstream
of PERK inhibits cytoprotective adaptation and promotes apoptosis.
(A) Synergistic effect of PA on MSeA-mediated ER stress in cell culture.
In the presence or absence of PA, HepG2 cells were exposed to MSeA
for 24 h, and then western blotting was used to evaluate the changes
of key ER stress markers. (B) Effect of PA and/or MSeA on the ER stress
makers in L02 cells were analyzed by western blotting. (C) Total apoptosis
induced by inhibition of IRE1 and exposure to PA in HepG2. (D) Effect
of inhibiting IRE1α and exposure to PA on the expression level
of cleaved-poly (ADP-ribose) polymerase (PARP) and ER stress-related
proteins in HepG2. (E) Effects of MSeA, PA, and the combination on
cleaved-PARP and phosphorylation of IRE1 measured by western blot in vivo.
PA Reduces the Expression
of GLUT1 in the Combined Anticancer
Effect of MSeA and Limits Glucose Metabolism
Cancer cells
have unique metabolic preferences, and they may upregulate the expression
of glucose-related proteins or activate related transporters to increase
glucose uptake.[30] We tested the effects
of MSeA and PA treatment on the expression of the glucose transporter
GLUT1. Western blot analysis confirmed that MSeA did not change the
expression of GLUT1, while the addition of PA reduced the level of
GLUT1 in HepG2 cells, whether in cell membrane protein or total cell
protein (Figure ).
Previous studies have shown that PA does not affect the content of
GLUT1 in LM3 cells, while with the addition of PA, GLUT4 decreases
in a dose-dependent manner.[3] This may be
because there are different results in different cells. In summary,
we concluded that PA may limit glucose metabolism by downregulating
GLUT1, making HepG2 more sensitive to MSeA-induced apoptosis.
Figure 4
PA restricts
glucose metabolism by regulating the expression of
GLUT1 in the anticancer combination with MSeA. Expression profile
of membrane GLUT1 (A) and total GLUT1 (B) in HepG2 cells after PA/MSeA
addition.
PA restricts
glucose metabolism by regulating the expression of
GLUT1 in the anticancer combination with MSeA. Expression profile
of membrane GLUT1 (A) and total GLUT1 (B) in HepG2 cells after PA/MSeA
addition.
Cotreatment with MSeA and
PA Induces Mitochondria-Dependent
Apoptosis in HepG2 Cells
The activation of the mitochondrial
pathway plays a key role in PA-mediated apoptosis.[31] The mitochondrial pathway is a major apoptosis signaling
pathway, and one of its characteristics is the destruction of the
mitochondrial membrane potential (MMP).[31,32] We first studied
the effect of MSeA on PA-mediated MMP destruction. As shown in Figure A, MSeA/PA cotreatment
resulted in a significant increase in the disruption of MMP. We further
examined the Bcl-2 family proteins under MSeA and/or PA exposure.
As shown in Figure B, MSeA/PA significantly increased the expression of Bim. In addition,
the increased cleavage of PARP and the downregulation of full-length
caspase-9 also proved the above results (Figure C). These data indicated that MSeA/PA induced
mitochondria-dependent apoptosis in HepG2 cells.
Figure 5
Combined treatment of
MSeA and PA induces mitochondria-mediated
apoptosis in HepG2 cells. The cells were treated with the indicated
concentrations of PA and/or MSeA for 24 h and then collected for mitochondrial
pathway analysis. (A) The results of flow cytometry showed that the
combination of MSeA and PA induced the enhancement of mitochondrial
permeability transition (MPT), following JC-1 staining. (B, C) Cells
were exposed to MSeA and/or PA for 24 h, and Bim, cleaved-PARP, and
cleaved-caspase-9 were analyzed by western blotting.
Combined treatment of
MSeA and PA induces mitochondria-mediated
apoptosis in HepG2 cells. The cells were treated with the indicated
concentrations of PA and/or MSeA for 24 h and then collected for mitochondrial
pathway analysis. (A) The results of flow cytometry showed that the
combination of MSeA and PA induced the enhancement of mitochondrial
permeability transition (MPT), following JC-1 staining. (B, C) Cells
were exposed to MSeA and/or PA for 24 h, and Bim, cleaved-PARP, and
cleaved-caspase-9 were analyzed by western blotting.
Discussion
PA is the most common saturated long-chain
fatty acid in the human
diet, and it acts as a signaling molecule to regulate various diseases
at the molecular level.[1] There are reports
that the intake of saturated fatty acids, such as PA, can cause diseases
related to lipotoxicity, and even cancer. However, in fact, owing
to different metabolic reprogramming processes, the carcinogenic effects
of PA on different cell types are distinct. As mentioned earlier,
PA has been reported to reduce the proliferation and metastatic invasion
in hepatocellular carcinoma. Furthermore, the addition of PA can reduce
the cell membrane fluidity and limit glucose metabolism.[1,3] In breast cancer cells, PA causes cell cycle delay in G2-phase and
leads to CHOP-dependent apoptosis.[4] Moreover,
PA addition increases the sensitivity of HER2-neutral and positive
breast cancer cells to trastuzumab treatment.[4] Recently, researchers have found that PA reduced the secretion of
exosomes in PC3humanprostate cancer cells in a concentration-dependent
manner.[6] In this study, we discovered that
PA addition increased the sensitivity of HepG2 cells to low-dose MSeA-induced
apoptosis (Figure B). Moreover, the combined effect of MSeA/PA was also demonstrated
in the HepG2 xenograft model (Figure ).It has been well established that apoptosis
is the main underlying
mechanism of the anticancer activity of selenium. Our finding revealed
that cotreating PA with MSeA induced apoptosis via the mitochondrial
pathway (Figure ).
Mitochondria is the very important organelle that regulates cell metabolism,
and its dysfunction is closely related to the occurrence and progression
of various metabolic diseases. Tumor cells need to sense and adapt
through metabolic reprogramming to survive, and mitochondria, as the
core of cell energy metabolism regulation, is closely related to the
metabolic adaptation of liver cancer cells. We found that PA may limit
glucose metabolism by downregulating GLUT1, making HepG2 more sensitive
to MSeA-induced apoptosis.Studies have shown the role of ERstress in selenium-mediated apoptosis.[28] Researchers have found that MSeA induced the
production of ER stress markers in PC3 cells, such as p-PERK, p-eIF2α,
and the apoptosis-related molecule CHOP.[33] Additionally, in the process of MSeA-induced apoptosis, CHOP may
be an important transcription factor. However, it has been shown that
HepG2 cells are insensitive to low-dose MSeA. One reason for this
may be that low-dose MSeA cannot induce CHOP expression in HepG2 cells
(Figure A). In our
study, the pro-apoptotic PERK signaling pathway was further enhanced
by the addition of both MSeA and PA, contributing to CHOP-dependent
cell death (Figure A). The UPR has contradictory results in different situations, including
rebuilding cell homeostasis and promoting cell apoptosis. The UPR
has three branches, of which IRE1 is the most conservative stress
sensor among the three branches.[34] IRE1
exerted both pro- and anti-apoptotic effects depending on the stress
conditions. We found that MSeA reduced the PA-induced p-IRE1 level
in HepG2 cells (Figure A) and in a xenograft mouse model (Figure E), suggesting its anti-apoptotic role in
MSeA/PA hepatoma chemotherapy. Using IRE1 inhibitor in PA-treated
HepG2 cells, we further verified the anti-apoptotic role of IRE1 under
such conditions (Figure C,D). This also showed that in the combined anticancer effect of
MSeA and PA, MSeA seems to act as an IRE1 inhibitor.Finally,
considering the potential lipotoxicity of PA, we performed
a similar experiment in L02 human normal liver cells. Interestingly,
we found that MSeA treatment protected against PA-induced cell death
in L02 cells. Due to the decrease in intracellular stress, the phosphorylation
levels of eIF2α and CHOP decreased. Surprisingly, the expression
of p-IRE1α was downregulated as well, suggesting its pro-apoptotic
effect in L02 cells. The IRE1 and PERK signaling pathways play the
same role, and the addition of MSeA relieves the intracellular stress
and protects the cells from PA lipotoxicity in L02 cells. The same
experiment was also verified in humanliver cancer cell SMMC-7721
(not shown in the data). Although the addition of 200 μM PA
significantly decreased cell viability, and there was no statistically
significant difference compared with the MSeA and PA combined treatment
group. The addition of IRE1 inhibitor 4μ8C caused a slight decrease
in cell viability, but the results were not statistically different.
From The Human Protein Atlas database (https://www.proteinatlas.org/), we know that the expression levels of IRE1 in HepG2 are relatively
high in many liver cancer cells, so we speculate that inhibiting IRE1
has a greater impact on the state of HepG2, which needs further research
to prove. In summary, our results confirmed that IRE1 played a prosurvival
role in PA-induced cell death. MSeA inhibited PA-induced p-IRE1α
and further enhanced the p-eIF2α and CHOP levels, which contributed
to the combination treatment-induced mitochondria-dependent apoptosis
in HepG2 cells. Taken together, our study revealed that PA may be
a promising sensitizer for improving the anticancer efficacy of MSeA
in hepatoma chemotherapy.
Materials and Methods
Chemicals and Reagents
Methylseleninic acid (MSeA,
purity >95%) and palmitic acid (PA) (P0500) were purchased from
Sigma-Aldrich
(St. Louis, MO). IRE1α inhibitor 4μ8C was purchased from
MCE (Shanghai, China). Primary antibodies specific for phospho-eIF2α
(3398), c-PARP (9546), Bip (3183), Bim (2933), and caspase-9 (9502)
were purchased from Cell Signaling Technology (Beverly, MA). Phospho-IRE1α
(ab48187) was purchased from Abcam (Cambridge, MA). CHOP (15204-1-AP)
was purchased from Protein Tech (Rosemont, IL). Secondary antibodies
specific for rabbit and mouse immunoglobulins were purchased from
MBL International Corporation (Woburn, MA).
Cell Culture and Treatment
Cells were maintained in
a humidified incubator at 37 °C and 5% CO2. The cell
lines HepG2 and L02 were obtained from the American Type Culture Collection
(ATCC). HepG2 cells were grown in Dulbecco’s modified Eagle’s
medium (DMEM) supplemented with 10% fetal bovine serum (FBS) without
antibiotics. L02 cells were cultured in RPMI-1640 Medium supplemented
with 10% FBS without antibiotics. When the degree of cell fusion reached
a suitable range, the medium was changed and then treated with the
corresponding reagents.
Crystal Violet Staining
The crystal
violet staining
was used to evaluate the effect of PA and/or MSeA on cell viability.
Cells were exposed to MSeA and/or PA for 24 h. After the treatments,
the medium was removed and the cells were fixed in 1% glutaraldehyde
solution in phosphate-buffered saline (PBS) for 15 min. The fixed
cells were stained with 0.02% crystal violet for 30 min. After washing
with PBS, the stained cells were dissolved with 70% ethanol. The absorbance
at 570 nm with the reference filter of 405 nm was measured with a
microplate reader (Thermo).
Apoptosis Evaluation
Apoptosis of
cells was determined
by Annexin V/PI double staining of externalized phosphatidylserine
(PS) by flow cytometry using a kit from MBL International Corporation
(Woburn, MA).
Western Blotting
The samples were
lysed with ice-cold
radioimmunoprecipitation assay (RIPA) buffer. An equal amount of the
sample protein was loaded onto the gel. After separation by electrophoresis,
the proteins were transferred to a nitrocellulose (NC) membrane. The
membrane was incubated with the primary antibody and then recognized
with the corresponding secondary antibody. Then, the immunoreacted
bands were obtained using an X-ray film. Western blot images were
quantitatively analyzed using ImageJ software.
Cell Membrane Protein Extraction
A membrane protein
extraction kit (Beyotime Biotechnology, P0033) was used to extract
cell membrane proteins, and the extracted proteins were used for the
next electrophoresis.
Wound-Healing Experiment
Cells were
seeded in a 6-well
culture plate at a density of 5 × 105 cells/well until
they grew to 90% confluence. Use a sterile 200 μL micropipette
tip to create a linear scratch in the monolayer of cells. The cells
were washed three times with PBS to remove the streaked cells and
then incubated in a medium without fetal bovine serum or a serum-free
medium containing drugs. Cell migration to the damaged area was observed
at 12 and 24 h.
Mitochondrial Membrane Potential Measurement
Mitochondrial
permeability transition (MPT) was determined using a JC-1 kit (M8650)
from Solarbio Life Science (Beijing, China). After it was stained,
flow cytometry was used to examine the changes of MPT.
Animals and
Treatments
The animal care and experimental
protocols in this study were approved by the Animal Care and Use Committee
of China Agricultural University. After 7 days of acclimatization,
all mice were randomly divided into four groups with three mice in
each group. To establish tumor xenografts, HepG2 cells (∼2
× 106) were mixed with 50% Matrigel (Corning, MA)
and injected subcutaneously into the right flank of 6–8 week-old
male BALB/c athymic nude mice (Charles River Laboratories, Beijing,
China). Tumors were measured with a caliper, and the tumor volume
was calculated according to the following formula: 1/2(w1 × w2 × w2), where w1 is
the maximum diameter of the tumor and w2 is the minimum diameter of the tumor. The body weight and tumor
volume were evaluated every other day. When the tumor volume was up
to about 100–120 mm3, continuous intragastric administration
of PA (10.26 mg/kg/day), MSeA (2 mg/kg/day), and their combination
medication were given for 20 days. At the end of the experiment, all
animals were euthanized. Tumor tissues were collected and stored at
−80 °C, and a portion of tumors from control and treated
animals were used to prepare tumor lysates for further analysis.
Statistical Analysis
All experiments have been carried
out at least three times, and the corresponding data are given. All
data are expressed as mean ± standard deviation (SD), and two-sided
Student’s t test was used for normally distributed
variables (*P < 0.05; **P <
0.01; ***P < 0.001). Multiple comparisons between
groups were made by one-way analysis of variance (ANOVA) with Tukey’s
post hoc test. Statistical significance was defined as P < 0.05 (*P < 0.05; **P <
0.01).
Authors: Hamsa Puthalakath; Lorraine A O'Reilly; Priscilla Gunn; Lily Lee; Priscilla N Kelly; Nicholas D Huntington; Peter D Hughes; Ewa M Michalak; Jennifer McKimm-Breschkin; Noburo Motoyama; Tomomi Gotoh; Shizuo Akira; Philippe Bouillet; Andreas Strasser Journal: Cell Date: 2007-06-29 Impact factor: 41.582
Authors: Saverio Stranges; Martin Laclaustra; Chen Ji; Francesco P Cappuccio; Ana Navas-Acien; Jose M Ordovas; Margaret Rayman; Eliseo Guallar Journal: J Nutr Date: 2009-11-11 Impact factor: 4.798